CA
NZ
UK
AU
IND
US
…
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bright Minds Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders using medicinal chemistry techniques, including deuteration, to optimize known small molecules. Long-term growth drivers include progression of clinical programs, potential licensing or partnership opportunities and addressing unmet needs in central nervous system therapies. Investors may find the company attractive for upside linked to clinical milestones and a platform that may benefit pharmacokinetic or safety profiles.
Key investment risks include high clinical and regulatory risk, no product revenue requiring additional financing, and competitive and execution risks typical of small, early-stage biotech companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Net income | -12.23M | -2.80M | -7.37M | -15.19M | -8.52M |
| Selling general administrative | 2.14M | 1.40M | 2.08M | 2.00M | 1.44M |
| Selling and marketing expenses | 0.43M | 0.04M | 0.12M | 0.55M | 0.85M |
| Gross profit | -0.08M | - | -0.07M | - | - |
| Reconciled depreciation | 0.08M | 0.07M | 0.07M | 0.01M | - |
| Ebit | -13.94M | -2.82M | -7.39M | -14.74M | -8.62M |
| Ebitda | -13.86M | -2.75M | -7.31M | -14.74M | -8.76M |
| Depreciation and amortization | 0.08M | 0.07M | 0.07M | 0.01M | - |
| Operating income | -13.94M | -2.82M | -7.39M | -14.74M | -8.76M |
| Other operating expenses | 13.94M | 2.82M | 7.39M | 14.73M | 8.60M |
| Interest expense | 0.03M | - | 0.02M | 0.22M | 0.00M |
| Interest income | 1.52M | 0.03M | 0.00M | - | - |
| Net interest income | 1.52M | 0.03M | 0.00M | 0.00M | -0.02M |
| Income tax expense | - | - | -0.01M | 0.22M | -0.14M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 13.94M | 2.82M | 7.39M | 14.73M | 8.60M |
| Cost of revenue | 0.06M | - | 0.07M | - | - |
| Total other income expense net | 1.71M | 0.02M | 0.01M | -0.22M | 0.11M |
| Net income from continuing ops | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Net income applicable to common shares | - | - | - | -14.96M | -8.65M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Intangible assets | - | - | - | - | 2000.00M |
| Other current assets | 0.99M | 0.22M | 0.03M | 0.16M | 0.17M |
| Total liab | 2.38M | 0.57M | 0.28M | 1.54M | 0.64M |
| Total stockholder equity | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
| Other current liab | 0.54M | 0.04M | 0.03M | 0.16M | 0.04M |
| Common stock | 123.25M | 35.42M | 33.91M | 32.24M | 27.08M |
| Capital stock | 123.25M | 35.42M | 33.91M | 32.24M | 27.08M |
| Retained earnings | -46.58M | -34.35M | -31.55M | -24.17M | -9.21M |
| Good will | - | - | - | - | -2000.00M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total current liabilities | 2.34M | 0.53M | 0.28M | 1.47M | 0.64M |
| Net debt | -82.78M | -5.60M | -6.67M | -11.49M | -19.76M |
| Short term debt | 0.08M | 0.08M | 0.07M | 0.07M | - |
| Short long term debt total | 0.13M | 0.12M | 0.07M | 0.14M | - |
| Other stockholder equity | - | 0.46M | 0.83M | 10542512.00M | -0.03M |
| Property plant equipment | - | - | - | 0.14M | - |
| Total current assets | 84.31M | 5.99M | 6.81M | 11.95M | 20.04M |
| Net tangible assets | - | - | - | 10.54M | 19.40M |
| Short term investments | 0.06M | - | 0.09M | - | - |
| Net receivables | 0.41M | 0.05M | 0.04M | 0.16M | 0.11M |
| Accounts payable | 1.71M | 0.41M | 0.18M | 1.25M | 0.60M |
| Accumulated other comprehensive income | 5.37M | 4.01M | 3.40M | 2.48M | 1.57M |
| Non currrent assets other | 0.03M | - | 0.00M | - | 0.00M |
| Non current assets total | 0.11M | 0.12M | 0.07M | 0.14M | 0.00M |
| Capital lease obligations | 0.13M | 0.12M | 0.07M | 0.14M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Change to liabilities | - | - | - | 0.77M | 0.51M |
| Net borrowings | -0.10M | -0.09M | -0.09M | -0.01M | -0.01M |
| Total cash from financing activities | 85.57M | 0.81M | 2.19M | 5.20M | 26.06M |
| Change to operating activities | - | - | - | -0.04M | -0.20M |
| Net income | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
| Change in cash | 77.19M | -1.03M | -4.88M | -8.13M | 18.96M |
| Begin period cash flow | 5.72M | 6.75M | 11.63M | 19.76M | 0.80M |
| End period cash flow | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total cash from operating activities | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Issuance of capital stock | 82.10M | 0.90M | 1.22M | 4.03M | 27.74M |
| Depreciation | 0.08M | 0.07M | 0.07M | 0.01M | 0.01M |
| Change to account receivables | -0.36M | -0.01M | 0.12M | - | - |
| Other cashflows from financing activities | -0.36M | 0.00M | 1.06M | 1.17M | -1.69M |
| Change to netincome | - | - | - | 0.65M | 1.03M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.55M | 0.04M | -0.94M | 0.73M | 0.31M |
| Stock based compensation | 3.18M | 0.84M | 1.15M | 0.88M | 0.88M |
| Other non cash items | -0.28M | -0.00M | 0.07M | -0.23M | 0.14M |
| Free cash flow | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences Inc |
-3.32 12.67% |
22.88 | - | - | - | 13.72 | -0.07 |
| NVO Novo Nordisk A/S |
-0.11 0.27% |
40.34 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-16.25 2.94% |
536.90 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.79 1.02% |
971.05 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Ian McDonald | Co-Founder, CEO, Pres & Director | 1988 |
| Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 1978 |
| Dr. Emer Leahy M.B.A., Ph.D. | Consultant | 1967 |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Interim Chief Science Officer & Director | NA |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 1955 |
| Dr. Gideon Shapiro Ph.D. | VP of Discovery | NA |
| Mr. Ian McDonald | Co-Founder, CEO, President & Director | 1989 |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 1965 |
| Mr. Ian McDonald | Co-Founder, CEO, President & Director | 1988 |
| Mr. Alex Vasilkevich | COO & Senior Scientific Officer | 1989 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.51%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.44%
Energy
-0.15%
Financial Services
-0.04%
Financials
+0.43%
Healthcare
+0.73%
Industrials
+0.57%
Real Estate
-0.32%
Technology
+1.29%
Utilities
+0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...